Leading conference selects Creoptix for its innovation platform

21.11.2014 07:49

Creoptix announces that it has been elected to participate at the SLAS Innovation AveNEW exhibition. This exhibition is part of the SLAS2015, the conference of the Society for Laboratory Automation and Screening attracting more than 5’000 attendees and takes place in Washington D.C. in February.

Kicking off the calendar year, SLAS2015 is the platform event for established companies launching new products and services. Innovation AveNEW is an in-kind, cost-sensitive program affording emerging, start-up companies the opportunity to actively engage and participate in a world-class event which helps to grow and scale their business as well as directly connects them with purchasing influencers and decision-makers from more than 40 countries.

One of the eight selected companies is Creoptix. “We are very excited to be part of the Innovation AveNEW program. Only few companies can participate in this especially promoted exhibition within the SLAS2015. It is an ideal platform for an emerging company like us to present our newly launched Creoptix WAVE to a large audience,” said Matyas Vegh, CEO of Creoptix AG. “The election is a great achievement and certainly validates the WAVE system as innovative laboratory instrument”.

About Creoptix AG
Creoptix AG is a privately‐held company focused on the development of next generation instruments for the high-sensitivity analysis of label-free molecular interactions based on an innovative, proprietary technology. Creoptix’ instruments are characterized by very high sensitivity while still being robust and customer-friendly. The main applications for its instruments are in the drug discovery industry and for life-science and materials research.

Comments

Please login or sign up to comment. Commenting guidelines

Principal

23.09.2016
Editorial

An IPO and CHF 50 million

Partners

Contributors